Obesity trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Obesity. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month36 studies across 16 companies, in the next 180 days.
August 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AMGN | Amgen | Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityNCT07229157Change from Baseline in QTcF for Maridebart Cafraglutide | Phase 1 | Active, not recruiting | 2026-08-26 | in 7 d | 2026-01-23 |
| LLY | Eli Lilly and Company | A Study of LY3971297 in Healthy ParticipantsNCT06148272Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Active, not recruiting | Aug 2026 | ≤ 12 d | 2026-07-16 |
September 2026 5
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide | Phase 1 | Active, not recruiting | 2026-09-03 | in 15 d | 2026-08-17 |
| PFE | Pfizer | A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesNCT06924320Occurrence of treatment-emergent adverse events (TEAEs) | Phase 1/2 | Recruiting | 2026-09-15 | in 27 d | 2026-06-01 |
| GPCR | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Aleniglipron Phase 2 in Type 2 Diabetes MellitusNCT07400588Incidence, severity and relationship of AEs/SAEs | Phase 2 | Active, not recruiting | Sep 2026 | ≤ 42 d | 2026-04-27 |
| LLY | Eli Lilly and Company | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804Percent Change from Baseline in Renal Sinus Fat Content (MRI) | Phase 2 | Active, not recruiting | Sep 2026 | ≤ 42 d | 2026-05-08 |
| NVO | Novo Nordisk A/S | Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.NCT07154238observationalDescription of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management | — | Enrolling by invitation | 2026-09-30 | in 42 d | 2025-11-25 |
October 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| MBX | MBX Biosciences | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With ObesityNCT07142707Number of participants with Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | 2026-10-30 | in 72 d | 2026-06-09 |
| RYTM | Rhythm Pharmaceuticals, Inc. | A Study of Setmelanotide in Patients With Prader-Willi SyndromeNCT06772597Frequency and severity of adverse events (AEs) | Phase 2 | Active, not recruiting | 2026-10-31 | in 73 d | 2026-02-12 |
November 2026 10
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USNCT07431086Occurrence of Treatment-Emergent Adverse Events (TEAEs) | Phase 2 | Active, not recruiting | 2026-11-13 | in 86 d | 2026-06-17 |
| AMGN | Amgen | Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711Maximum Observed Concentration (Cmax) of COC | Phase 1 | Active, not recruiting | 2026-11-18 | in 91 d | 2026-07-20 |
| SKYE | Skye Bioscience, Inc. | Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboNCT06577090Percent change in body weight (main study) | Phase 2 | Active, not recruiting | 2026-11-20 | in 93 d | 2026-01-14 |
| BIOA | BioAge Labs, Inc. | A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsNCT07656727Percent change in hsCRP (Dose A) | Phase 2 | Recruiting | 2026-11-30 | in 103 d | 2026-06-18 |
| LLY | Eli Lilly and Company | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045Change from Baseline in Apnea-Hypopnea Index (AHI) | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 103 d | 2025-09-29 |
| LLY | Eli Lilly and Company | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383Percent Change from Baseline in Body Weight | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 103 d | 2026-07-20 |
| LLY | Eli Lilly and Company | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightNCT06914895Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 103 d | 2026-05-12 |
| LLY | Eli Lilly and Company | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightNCT06962280Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 103 d | 2026-02-17 |
| LLY | Eli Lilly and Company | A Study of LY4064912 in Healthy Participants and With Overweight or ObesityNCT07152002Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Active, not recruiting | Nov 2026 | ≤ 103 d | 2026-08-18 |
| LLY | Eli Lilly and Company | A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes MellitusNCT07299084Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test Meal | Phase 1 | Active, not recruiting | Nov 2026 | ≤ 103 d | 2026-05-19 |
December 2026 9
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| RANI | RANI Therapeutics | An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.NCT06891287To evaluate safety and tolerability of RT-114 by assessing treatment emergent adverse events (TEAEs) | Phase 1 | Recruiting | 2026-12-01 | in 104 d | 2026-04-14 |
| VNDA | Vanda Pharmaceuticals | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseNCT07446439Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary. | Phase 3 | Recruiting | 2026-12-01 | in 104 d | 2026-04-20 |
| NVO | Novo Nordisk A/S | Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No) | Phase 1 | Recruiting | 2026-12-13 | in 116 d | 2026-07-21 |
| NVO | Novo Nordisk A/S | A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityNCT07184632Part A: Number of treatment-emergent adverse events (TEAE) | Phase 2 | Active, not recruiting | 2026-12-14 | in 117 d | 2026-05-07 |
| NVO | Novo Nordisk A/S | A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or ObesityNCT07566390Number of treatment emergent adverse events (TEAEs) | Phase 1 | Recruiting | 2026-12-26 | in 129 d | 2026-08-04 |
| LLY | Eli Lilly and Company | A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise HealthyNCT07225556Number and Incidence of Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Dec 2026 | ≤ 134 d | 2026-07-29 |
| LLY | Eli Lilly and Company | A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightNCT07738614Acetaminophen Area Under the Concentration Versus Time Curve (AUC) | Phase 1 | Not yet recruiting | Dec 2026 | ≤ 134 d | 2026-07-31 |
| PHN.MI | Pharmanutra S.p.a. | Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss TreatmentNCT07393360Change in Appendicular Skeletal Muscle Mass (ASMM) | Not applicable | Recruiting | Dec 2026 | ≤ 134 d | 2026-03-23 |
| VANI | Vivani Medical, Inc | Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide ImplantNCT07430059Area under the plasma concentration-time curve (AUC) | Phase 1 | Not yet recruiting | Dec 2026 | ≤ 134 d | 2026-06-30 |
January 2027 7
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or ObesityNCT07725809Pharmacokinetics (PK): Area Under the Curve (AUC) of PF-08653945 | Phase 1 | Not yet recruiting | 2027-01-13 | in 147 d | 2026-07-24 |
| NVO | Novo Nordisk A/S | A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or ObesityNCT07395687Part A - Number of treatment emergent adverse events (TEAEs) | Phase 2 | Recruiting | 2027-01-14 | in 148 d | 2026-04-21 |
| AMGN | Amgen | Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839Percent Change From Baseline in Body Weight at Week 72 | Phase 3 | Active, not recruiting | 2027-01-21 | in 155 d | 2025-10-20 |
| NVO | Novo Nordisk A/S | A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or ObesityNCT07437079Number of treatment emergent adverse events (TEAE) - Part A | Phase 1 | Recruiting | 2027-01-21 | in 155 d | 2026-07-29 |
| NVO | Novo Nordisk A/S | A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560Number of Treatment Emergent Adverse Events (TEAEs) nausea, vomiting and diarrhoea | Phase 1 | Recruiting | 2027-01-26 | in 160 d | 2026-04-13 |
| PFE | Pfizer | A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or ObesityNCT07508241Acetaminophen Pharmacokinetic (PK) Parameters: Maximum observed plasma concentration (Cmax) | Phase 1 | Active, not recruiting | 2027-01-27 | in 161 d | 2026-07-09 |
| AZN | AstraZeneca | A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightNCT06151964Number and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study. | Phase 1/2 | Active, not recruiting | 2027-01-29 | in 163 d | 2026-06-23 |
February 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| GUTS | Fractyl Health Inc. | Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on TirzepatideNCT06484114To demonstrate that Revita DMR is superior to sham in percent change in body weight from baseline to week 26 | Not applicable | Active, not recruiting | 2027-02-15 | in 180 d | 2026-03-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Obesity
most recently updated first525 studies match. Showing the first 100 of 525 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 DiabetesNCT06945419Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Completed | Drug: LY4086940, Placebo, LY4086940 | Healthy, Overweight, Obesity, Type 2 Diabetes | 219 | 2025-04-23 | 2026-08-05actual | — | 2026-08-19 |
| NVO | Novo Nordisk A/S | — | A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With ObesityNCT07693868Part A: Area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single dose | Phase 1 | Recruiting | Drug: NNC6022-0004, Placebo | Obesity, Elevated High-sensitivity C-reactive Protein (hsCRP) | 128 | 2026-07-06 | 2027-08-01 | in 347 d | 2026-08-19 |
| ARWR | Arrowhead Pharmaceuticals | $12.4B | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06700538Number of Participants with Treatment-Emergent Adverse Events (TEAEs) | Phase 1/2 | Recruiting | Drug: ARO-INHBE, Placebo, Tirzepatide | Obesity | 180 | 2024-12-04 | 2027-09-17 | in 394 d | 2026-08-18 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4064912 in Healthy Participants and With Overweight or ObesityNCT07152002Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Active, not recruiting | Drug: LY4064912, LY4064912, Placebo, Placebo | Overweight or Obesity, Healthy | 144 | 2025-08-28 | Nov 2026 | ≤ 103 d | 2026-08-18 |
| NVO | Novo Nordisk A/S | — | A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001Time to first occurrence of a composite Heart Failure (HF) endpoint consisting of cardiovascular (CV) death | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo | Obesity, Heart Failure | 5,610 | 2026-05-11 | 2029-07-23 | in 1,069 d | 2026-08-18 |
| NVO | Novo Nordisk A/S | — | A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body WeightNCT07710768AUC0-∞,s-warfarin: The area under the plasma s-warfarin concentration-time curve extrapolated to infinity after single dose | Phase 1 | Recruiting | Drug: UBT251, Cocktail (Warfarin/Caffeine/Midazolam) | Obesity, Overweight | 44 | 2026-07-15 | 2027-04-07 | in 231 d | 2026-08-18 |
| NVO | Novo Nordisk A/S | — | Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body WeightNCT07770841Relative change in body weight | Phase 3 | Recruiting | Drug: Semaglutide, Placebo | Overweight, Obesity | 450 | 2026-08-12 | 2028-02-22 | in 552 d | 2026-08-18 |
| NVO | Novo Nordisk A/S | — | A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or ObesityNCT06577766Part A: Number of treatment emergent adverse events (TEAE) | Phase 1 | Active, not recruiting | Drug: NNC0638-0355, Placebo (NNC0638-0355) | Obesity, Overweight | 63 | 2024-09-03 | 2027-10-11 | in 418 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityNCT07311850Percent change from baseline in body weight | Phase 3 | Active, not recruiting | Drug: MET097, Placebo | Obesity and Overweight | 3,578 | 2025-12-19 | 2027-09-21 | in 398 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or ObesityNCT07400679Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of PF-08653944 | Phase 1 | Completed | Drug: PF-08653944 | Overweight, Obesity, Healthy | 48 | 2026-02-04 | 2026-07-02actual | — | 2026-08-17 |
| NVO | Novo Nordisk A/S | — | AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07509307Relative change in body weight | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity, Overweight, Osteoarthritis, Knee | 400 | 2026-04-20 | 2028-08-14 | in 726 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)NCT07575932Percent change from baseline in body weight | Phase 2 | Recruiting | Drug: PF-08653945, PF-08653944, Placebo | Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity, Overnutrition, Nutrition Disorders, Nutritional and Metabolic Diseases, Body Weight | 872 | 2026-05-11 | 2027-08-04 | in 350 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or ObesityNCT07595549Percent change from baseline in body weight | Phase 3 | Recruiting | Drug: PF-08653944 · Other: Placebo | Obesity, Overweight and/or Obesity, Overweight | 954 | 2026-06-10 | 2028-05-04 | in 624 d | 2026-08-17 |
| NVO | Novo Nordisk A/S | — | A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide | Phase 1 | Active, not recruiting | Drug: Cagrilintide B, Cagrilintide D | Overweight, Obesity | 50 | 2026-05-20 | 2026-09-03 | in 15 d | 2026-08-17 |
| NVO | Novo Nordisk A/S | — | A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or ObesityNCT07767175Part A: Number of treatment emergent adverse events (TEAE) | Phase 1 | Not yet recruiting | Drug: NNC0721-8060, Semaglutide, Placebo | Overweight, Obesity | 142 | 2026-08-12 | 2027-09-23 | in 400 d | 2026-08-17 |
| NVO | Novo Nordisk A/S | — | Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With ObesityNCT05132088results2026-08-14Percent Change From Baseline in Body Weight | Phase 3 | Completed | Drug: semaglutide 50 mg, placebo (semaglutide) | Overweight and Obesity | 201 | 2021-11-16 | 2023-07-11actual | — | 2026-08-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903results2026-08-14Percent Change From Baseline in Body Weight (Primary Treatment Period) | Phase 3 | Active, not recruiting | Drug: Orforglipron, Placebo | Obesity, Overweight, Overweight or Obesity | 3,127 | 2023-06-05 | 2025-07-25actual | — | 2026-08-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07765511Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Not yet recruiting | Drug: Macupatide, Eloralintide, Placebo | Obesity, Overweight | 60 | Oct 2026 | Jun 2027 | ≤ 315 d | 2026-08-14 |
| BSX | Boston Scientific Corporation | $73.1B | Safety and Effectiveness of Orbera365™ Intragastric Balloon SystemNCT07062094observationalRate of Subjects with Serious Adverse Events | — | Recruiting | Device: Intragastric Balloon | Obesity | 200 | 2026-04-07 | 2028-04-07 | in 597 d | 2026-08-13 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846Part A: Frequency of Adverse Events (AEs) | Phase 1/2 | Recruiting | Drug: ALN-2232, Placebo, Tirzepatide | Obesity | 156 | 2026-03-02 | 2027-04-27 | in 251 d | 2026-08-12 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | A Study to Evaluate ALN-6222 in Participants With ObesityNCT07624071Frequency of Adverse Events | Phase 1 | Recruiting | Drug: ALN-6222, Placebo | Obesity | 88 | 2026-06-04 | 2027-12-14 | in 482 d | 2026-08-12 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or PlaceboNCT07757087Change in sleeping metabolic rate (SMR) | Phase 1 | Recruiting | Drug: NNC0487-0111, Placebo · Behavioral: LED | Overweight, Obesity | 120 | 2026-08-03 | 2028-09-18 | in 761 d | 2026-08-11 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.9B | A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756results2026-05-29Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen | Phase 3 | Active, not recruiting | Drug: Setmelanotide, Placebo | Hypothalamic Obesity | 143 | 2023-04-26 | 2025-03-18actual | — | 2026-08-10 |
| AZN | AstraZeneca | — | A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.NCT07511205Number of participants with adverse events (AEs), serious adverse events (SAEs), AE leading to discontinuation (DAEs), and AEs of special interest (AESIs) | Phase 1 | Recruiting | Drug: AZD1043 · Other: Placebo | Healthy Participants, Obesity | 104 | 2026-03-30 | 2027-04-09 | in 233 d | 2026-08-10 |
| GPCR | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | $11.5B | Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)NCT07654361Percent change in body weight from Baseline | Phase 3 | Recruiting | Drug: Aleniglipron, Placebo | Obesity, Overweight, Chronic Weight Management | 3,600 | 2026-07-13 | Sep 2028 | ≤ 773 d | 2026-08-10 |
| GPCR | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | $11.5B | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374Percent change in body weight from Baseline | Phase 3 | Recruiting | Drug: aleniglipron, aleniglipron, aleniglipron, Placebo | Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus | 1,100 | 2026-07-17 | Sep 2028 | ≤ 773 d | 2026-08-10 |
| NVO | Novo Nordisk A/S | — | A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose WeightNCT05726227Group Kids: Change in body mass index (BMI) | Phase 3 | Active, not recruiting | Drug: Semaglutide, Placebo | Obesity | 210 | 2023-07-07 | 2025-10-15actual | — | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277Percent Change from Baseline in Body Mass Index (BMI) | Phase 3 | Recruiting | Drug: Tirzepatide, Placebo | Obesity, Weight Gain | 300 | 2024-06-03 | Oct 2027 | ≤ 438 d | 2026-08-07 |
| ABBV | AbbVie | $457.5B | A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With ObesityNCT07291232Number of Participants with Adverse Events (AEs) | Phase 1 | Recruiting | Drug: ABBV-295, Placebo | Obesity | 80 | 2025-11-19 | Mar 2027 | ≤ 224 d | 2026-08-07 |
| AMGN | Amgen | $229.9B | A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsNCT07313761Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Infinity (AUCinf) of AMG 133 | Phase 1 | Completed | Drug: Maridebart Cafraglutide | Overweight and Obesity | 349 | 2025-12-15 | 2026-07-02actual | — | 2026-08-07 |
| ABBV | AbbVie | $457.5B | Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979Percent Change From Baseline in Body Weight | Phase 2 | Not yet recruiting | Drug: ABBV-295, Placebo | Obesity, Overweight | 360 | 2026-08-07 | Mar 2028 | ≤ 590 d | 2026-08-07 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.9B | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayNCT05093634Difference in mean change in body weight in patients treated with setmelanotide compared to placebo, assessed as percent change in BMI | Phase 3 | Completed | Drug: Setmelanotide, Placebo | Obesity, Genetic Obesity | 296 | 2021-12-10 | 2025-12-22actual | — | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956Number of Participants Allocated to Each ISA | Phase 2 | Recruiting | Drug: LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo, Placebo | Obesity, Overweight | 1,481 | 2023-11-17 | Sep 2027 | ≤ 407 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction | Phase 3 | Recruiting | Drug: Mirikizumab, Mirikizumab, Tirzepatide, Placebo | Ulcerative Colitis, Obesity or Overweight | 350 | 2025-06-26 | Apr 2028 | ≤ 620 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction | Phase 3 | Recruiting | Drug: Mirikizumab, Mirikizumab, Tirzepatide, Placebo | Crohn's Disease, Obesity or Overweight | 290 | 2025-06-26 | May 2028 | ≤ 651 d | 2026-08-06 |
| NVO | Novo Nordisk A/S | — | Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642Relative change in body weight | Phase 3 | Active, not recruiting | Drug: Cagrilintide, Placebo | Obesity, Overweight | 300 | 2025-11-05 | 2027-05-11 | in 265 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600Percent Change from Baseline in Body Weight | Phase 3 | Recruiting | Drug: Eloralintide, Placebo | Overweight, Obesity | 1,035 | 2025-12-15 | Jan 2028 | ≤ 530 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886Percent Change from Baseline in Body Weight | Phase 3 | Recruiting | Drug: Eloralintide, Placebo | Obesity, Overweight | 1,980 | 2026-02-06 | Mar 2028 | ≤ 590 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931Percent Change from Baseline in Body Weight | Phase 3 | Recruiting | Drug: Eloralintide, Placebo | Osteoarthritis, Overweight or Obesity | 900 | 2026-02-09 | Mar 2028 | ≤ 590 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011Percent Change from Baseline in Body Weight | Phase 3 | Recruiting | Drug: Eloralintide, Placebo | Sleep Apnea, Obstructive, Obesity, Overweight | 800 | 2026-02-10 | Mar 2028 | ≤ 590 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190Percent Change from Baseline in Body Weight | Phase 3 | Recruiting | Drug: Eloralintide, Placebo | Overweight, Obesity | 900 | 2026-02-10 | Jun 2028 | ≤ 681 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightNCT07589608Percent Change from Baseline in Body Weight | Phase 2 | Recruiting | Drug: Macupatide, Eloralintide, Placebo | Overweight, Obesity | 400 | 2026-05-15 | Sep 2027 | ≤ 407 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | Pre-approval Expanded Access of Retatrutide (LY3437943)NCT07629401expanded access | — | Available | Drug: Retatrutide | Obesity, Obesity-related Complications | — | — | — | — | 2026-08-06 |
| BSX | Boston Scientific Corporation | $73.1B | Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT LossNCT06894498observationalProportion of subjects that maintain clinically significant weightloss at five-year visit | — | Terminatedsponsor's stated reason: Business decision. | Other: No Intervention: Observational Cohort | Obesity and Obesity-related Medical Conditions, Weight Loss | 2 | 2026-03-31 | 2026-07-30actual | — | 2026-08-04 |
| NVO | Novo Nordisk A/S | — | A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical PracticeNCT07055607observationalAbsolute change in body weight (kilograms [kg]) | — | Enrolling by invitation | Drug: Semaglutide | Obesity | 1,250 | 2025-05-01 | 2028-08-15 | in 727 d | 2026-08-04 |
| AMGN | Amgen | $229.9B | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686Change in Apnea-Hypopnea Index (AHI) from baseline at week 52 | Phase 3 | Recruiting | Drug: Maridebart cafraglutide, Placebo | Obesity, Obstructive Sleep Apnea | 250 | 2025-12-19 | 2027-09-29 | in 406 d | 2026-08-04 |
| NVO | Novo Nordisk A/S | — | AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07533175Relative change in body weight | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Diabetes Mellitus, Overweight, Obesity | 630 | 2026-04-13 | 2028-08-07 | in 719 d | 2026-08-04 |
| NVO | Novo Nordisk A/S | — | A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or ObesityNCT07566390Number of treatment emergent adverse events (TEAEs) | Phase 1 | Recruiting | Drug: NNC0113-5840, Placebo | Obesity, Overweight | 48 | 2026-05-01 | 2026-12-26 | in 129 d | 2026-08-04 |
| NVO | Novo Nordisk A/S | — | AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109Relative change in body weight | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity, Overweight, Obstructive Sleep Apnoea | 300 | 2026-05-05 | 2028-06-26 | in 677 d | 2026-08-04 |
| AMGN | Amgen | $229.9B | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235Percent Change in Body Weight from Baseline of the Parent Trial (20210181) | Phase 3 | Recruiting | Drug: Maridebart cafraglutide, Placebo | Obesity, Overweight | 3,200 | 2026-07-23 | 2027-12-26 | in 494 d | 2026-08-04 |
| NVO | Novo Nordisk A/S | — | A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightNCT07745504Relative change in body weight | Phase 3 | Not yet recruiting | Drug: Cagrilintide, Placebo cagrilintide, Placebo semaglutide | Overweight, Obesity | 285 | 2026-08-04 | 2027-05-18 | in 272 d | 2026-08-04 |
| NVO | Novo Nordisk A/S | — | Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759Relative change in body weight | Phase 3 | Active, not recruiting | Drug: Cagrilintide, Placebo (matched to Cagrilintide) | Overweight, Obesity, Type 2 Diabetes | 330 | 2025-11-05 | 2027-05-12 | in 266 d | 2026-08-03 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792Number of Participants Allocated to Each Study | Phase 3 | Active, not recruiting | Drug: Orforglipron, Placebo | Obesity, Overweight, Type 2 Diabetes | 1,400 | 2025-05-15 | Aug 2027 | ≤ 377 d | 2026-07-31 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightNCT07738614Acetaminophen Area Under the Concentration Versus Time Curve (AUC) | Phase 1 | Not yet recruiting | Drug: Eloralintide, Placebo, Acetaminophen | Obesity, Overweight | 56 | Jul 2026 | Dec 2026 | ≤ 134 d | 2026-07-31 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045Percent Change from Baseline in Body Weight | Phase 3 | Completed | Drug: Retatrutide, Placebo | Obesity, Cardiovascular Diseases | 1,946 | 2023-05-30 | 2026-04-16actual | — | 2026-07-30 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079Percent Change from Baseline in Body Weight | Phase 3 | Completed | Drug: Retatrutide, Placebo | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 1,152 | 2023-07-11 | 2026-06-16actual | — | 2026-07-30 |
| NVO | Novo Nordisk A/S | — | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414Relative change in body weight | Phase 3 | Recruiting | Drug: Cagrisema, Semaglutide | Obesity, Type 2 Diabetes | 2,500 | 2026-05-21 | 2028-02-23 | in 553 d | 2026-07-30 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459Percent Change from Baseline in Body Weight | Phase 3 | Active, not recruiting | Drug: Orforglipron, Placebo | Obesity, Overweight | 800 | 2025-05-15 | Aug 2027 | ≤ 377 d | 2026-07-29 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise HealthyNCT07225556Number and Incidence of Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: LY4167586, Placebo, LY4167586 | Overweight, Obesity | 84 | 2025-11-18 | Dec 2026 | ≤ 134 d | 2026-07-29 |
| NVO | Novo Nordisk A/S | — | A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or ObesityNCT07437079Number of treatment emergent adverse events (TEAE) - Part A | Phase 1 | Recruiting | Drug: NNC6989-0001, Placebo (NNC6989-0001) | Overweight, Obesity | 132 | 2026-02-24 | 2027-01-21 | in 155 d | 2026-07-29 |
| GUBRA.CO | Gubra A/S | — | A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2DNCT07702890Number of Treatment Emergent Adverse Events | Phase 1/2 | Recruiting | Drug: GUB-UCN2, Placebo | Obesity, Type 2 Diabetes | 188 | Jul 2026 | Dec 2028 | ≤ 865 d | 2026-07-29 |
| PFE | Pfizer | $155.3B | A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have ObesityNCT07731139Incidence of treatment emergent adverse events (TEAE) | Phase 1 | Not yet recruiting | Drug: PF-08642534, Placebo | Obesity | 120 | 2026-07-28 | 2027-04-21 | in 245 d | 2026-07-28 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653Percent Change from baseline in body weight | Phase 3 | Active, not recruiting | Drug: PF-08653944 · Other: Placebo | Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2, Type 2 Diabetes | 1,044 | 2026-02-24 | 2027-10-12 | in 419 d | 2026-07-27 |
| NVO | Novo Nordisk A/S | — | A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667Relative change in body weight | Phase 3 | Active, not recruiting | Drug: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Obesity | 609 | 2025-06-03 | 2027-03-01 | in 194 d | 2026-07-24 |
| AMGN | Amgen | $229.9B | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE]) | Phase 3 | Recruiting | Drug: Maridebart Cafraglutide, Placebo | Atherosclerotic Cardiovascular Disease, Overweight, Obesity | 12,800 | 2025-07-25 | 2028-06-30 | in 681 d | 2026-07-24 |
| BSX | Boston Scientific Corporation | $73.1B | RESCUE: Discontinuation of GLP-1NCT07190794observationalPercent total body weight loss (TBWL) at 1 year from baseline | — | Terminatedsponsor's stated reason: Business decision | Device: OverStitch™ or OverStitch NXT™ · Behavioral: Lifestyle Modification | Obesity | 18 | 2025-12-17 | 2026-05-26actual | — | 2026-07-24 |
| PFE | Pfizer | $155.3B | A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or ObesityNCT07725809Pharmacokinetics (PK): Area Under the Curve (AUC) of PF-08653945 | Phase 1 | Not yet recruiting | Drug: PF-08653945 | Overweight, Obesity, Healthy | 57 | 2026-07-23 | 2027-01-13 | in 147 d | 2026-07-24 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093Change from Baseline in Pain Intensity Per Numeric Rating Scale | Phase 3 | Active, not recruiting | Drug: Retatrutide, Placebo | Obesity, Overweight, Chronic Low Back Pain (CLBP) | 586 | 2025-05-29 | Sep 2027 | ≤ 407 d | 2026-07-23 |
| AMGN | Amgen | $229.9B | Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399Percent Change from Baseline in Body Weight at Week 68 | Phase 3 | Recruiting | Drug: Maridebart Cafraglutide | Obesity or Overweight | 300 | 2026-05-11 | 2028-01-03 | in 502 d | 2026-07-23 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939Percent Change from Baseline in Body Mass Index (BMI) | Phase 3 | Recruiting | Drug: Orforglipron, Placebo | Obesity, Overweight | 150 | 2024-11-18 | Dec 2027 | ≤ 499 d | 2026-07-22 |
| NVO | Novo Nordisk A/S | — | AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightNCT07720271Relative change in body weight | Phase 3 | Not yet recruiting | Drug: zenagamtide, Placebo | Overweight, Obesity | 950 | 2026-09-01 | 2028-06-27 | in 678 d | 2026-07-22 |
| NVO | Novo Nordisk A/S | — | A Study to Evaluate the Safety of Exposure to Wegovy During PregnancyNCT05503927observationalNumber of Infants with Major Congenital Malformation (MCM) | — | Enrolling by invitation | Other: No Intervention | Pregnancy, Obesity, Overweight | 2,701 | 2020-02-01 | 2027-08-15 | in 361 d | 2026-07-21 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationNCT06299098Incidence of treatment-emergent adverse events (TEAEs) | Phase 2 | Active, not recruiting | Drug: Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide, Matching Placebo-Part A, Matching Placebo-Trevogrumab, Matching Placebo-Garetosmab | Obesity | 1,005 | 2024-03-13 | 2026-05-06actual | — | 2026-07-21 |
| NVO | Novo Nordisk A/S | — | Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No) | Phase 1 | Recruiting | Drug: Liraglutide, Oral Semaglutide, Semaglutide | Obesity | 71 | 2025-11-07 | 2026-12-13 | in 116 d | 2026-07-21 |
| NVO | Novo Nordisk A/S | — | AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose WeightNCT07668401Relative change in body weight | Phase 3 | Not yet recruiting | Drug: Zenagamtide, Placebo ( matched to Zenagamtide) | Obesity, Overweight | 400 | 2027-01-07 | 2029-01-11 | in 876 d | 2026-07-21 |
| AMGN | Amgen | $229.9B | A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityNCT07717814Maximum Observed Concentration (Cmax) of AMG 133 | Phase 1 | Completed | Drug: AMG 133 (frozen liquid), AMG 133 (liquid) | Overweight and Obesity | 154 | 2024-11-26 | 2025-05-22actual | — | 2026-07-21 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseNCT05931380results2026-07-20Percent Change From Baseline in Body Weight at Week 72 | Phase 3 | Completed | Drug: Orforglipron, Placebo | Obesity | 238 | 2023-07-31 | 2025-06-19actual | — | 2026-07-20 |
| AZN | AstraZeneca | — | A Study in Participants With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06595238Percent change in body weight from baseline to week 26 | Phase 2 | Completed | Drug: AZD6234, Placebo comparator | Obesity or Overweight | 262 | 2024-10-01 | 2025-12-03actual | — | 2026-07-20 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383Percent Change from Baseline in Body Weight | Phase 3 | Active, not recruiting | Drug: Retatrutide, Tirzepatide | Obesity | 800 | 2024-11-01 | Nov 2026 | ≤ 103 d | 2026-07-20 |
| LLY | Eli Lilly and Company | $1.15T | A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549Number of Participants Allocated to Each ISA | Phase 3 | Recruiting | Drug: Orforglipron, Placebo | Obesity, Overweight | 125 | 2024-11-18 | Feb 2027 | ≤ 193 d | 2026-07-20 |
| AMGN | Amgen | $229.9B | Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711Maximum Observed Concentration (Cmax) of COC | Phase 1 | Active, not recruiting | Drug: COC, Maridebart Cafraglutide | Overweight, Obesity | 49 | 2026-04-09 | 2026-11-18 | in 91 d | 2026-07-20 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796CagriSema versus placebo: Relative change in body weight | Phase 3 | Active, not recruiting | Drug: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Obesity | 3,400 | 2022-11-01 | 2024-10-30actual | — | 2026-07-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related ComorbiditiesNCT06023095results2026-07-17Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Completed | Drug: LY3502970, Placebo | Overweight, Obesity | 24 | 2023-09-21 | 2024-07-29actual | — | 2026-07-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightNCT06440980results2026-07-17Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7 | Phase 1 | Completed | Drug: Orforglipron | Healthy, Obese, Overweight, Obesity | 533 | 2024-06-24 | 2025-06-02actual | — | 2026-07-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571Percent Change from Baseline in Body Weight | Phase 2 | Active, not recruiting | Drug: LY3841136, Tirzepatide, Placebo | Obesity, Overweight | 367 | 2024-09-20 | 2026-07-01actual | — | 2026-07-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559Percent Change from Baseline in Body Weight | Phase 2 | Recruiting | Drug: Macupatide, Eloralintide, Macupatide Placebo, Eloralintide Placebo | Obesity, Overweight, Diabetes Mellitus, Type 2 | 200 | 2025-10-16 | Mar 2027 | ≤ 224 d | 2026-07-17 |
| NVO | Novo Nordisk A/S | — | A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285Relative change in body mass index (BMI) | Phase 3 | Recruiting | Drug: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Overweight, Obesity | 460 | 2026-01-08 | 2030-03-20 | in 1,309 d | 2026-07-17 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become PregnantNCT07710729AUC,EE,SS: The area under the EE plasma concentration time curve during a dosing interval at steady state | Phase 1 | Not yet recruiting | Drug: UBT251, Oral contraceptive, Acetaminophen | Overweight, Obesity | 40 | 2026-07-17 | 2027-04-27 | in 251 d | 2026-07-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3971297 in Healthy ParticipantsNCT06148272Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Active, not recruiting | Drug: LY3971297, Placebo, LY3971297 IV | Healthy, Obesity, Hypertension | 225 | 2023-12-07 | Aug 2026 | ≤ 12 d | 2026-07-16 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or ObesityNCT07476118Percent Change in Body Weight | Phase 1 | Active, not recruiting | Drug: Brenipatide · Other: Placebo | Obesity, Overweight | 150 | 2026-03-18 | Feb 2027 | ≤ 193 d | 2026-07-16 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise HealthyNCT07654972Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Recruiting | Drug: LY4174794, LY4174794, Placebo | Obesity, Overweight | 108 | 2026-06-24 | Apr 2029 | ≤ 985 d | 2026-07-16 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityNCT07665879Change From Baseline In Hyperinsulinemic Euglycemic Clamp (HEC) Predicted Clamp-Derived Insulin Sensitivity (M-value) | Phase 1 | Recruiting | Drug: Eloralintide · Other: Placebo | Overweight, Obesity | 115 | 2026-06-24 | Aug 2027 | ≤ 377 d | 2026-07-16 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.9B | Open-Label Extension Study of SetmelanotideNCT06596135Safety and tolerability of setmelanotide assessed by frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 3 | Completed | Drug: Setmelanotide | Obesity Associated With Defects in Leptin-melanocortin Pathway | 28 | 2024-10-21 | 2026-06-24actual | — | 2026-07-15 |
| NVO | Novo Nordisk A/S | — | AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571005Relative change in body weight | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity, Overweight, Obstructive Sleep Apnoea | 300 | 2026-05-05 | 2028-07-12 | in 693 d | 2026-07-13 |
| LLY | Eli Lilly and Company | $1.15T | A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05841238results2026-07-10Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13 | Phase 1 | Completed | Drug: LY3502970 | Healthy, Obese | 52 | 2023-04-26 | 2023-09-14actual | — | 2026-07-10 |
| NVO | Novo Nordisk A/S | — | A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityNCT07639021Number of gastrointestinal adverse events | Phase 2 | Recruiting | Drug: NNC0662-0419, Semaglutide, NNC0662-0419 Placebo, Semaglutide placebo | Obesity | 230 | 2026-06-09 | 2027-07-12 | in 327 d | 2026-07-10 |
| NVO | Novo Nordisk A/S | — | SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityNCT04775082Relative change in BMI (Body mass index) | Phase 3 | Active, not recruiting | Drug: Liraglutide, Placebo | Obesity | 78 | 2021-03-04 | 2023-08-01actual | — | 2026-07-09 |
| NVO | Novo Nordisk A/S | — | AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightNCT07339423Relative change in body weight | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity | 1,150 | 2026-02-24 | 2029-06-26 | in 1,042 d | 2026-07-09 |
| NVO | Novo Nordisk A/S | — | A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766Relative change in body weight | Phase 3 | Withdrawnsponsor's stated reason: The study is withdrawn due to strategic reasons. | Drug: Cagrisema, Placebo CagriSema | Overweight, Obesity | 0 | 2026-06-22 | 2027-11-29 | in 467 d | 2026-07-09 |
| NVO | Novo Nordisk A/S | — | A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630Relative change in body weight | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111 ) | Obesity, Knee Osteoarthritis (OA) | 400 | 2026-04-13 | 2028-08-14 | in 726 d | 2026-07-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Obesity is matched — 24 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Obesity
- Overweight or Obesity
- Obese
- Overweight and Obesity
- Obesity or Overweight
- Hypothalamic Obesity
- Obesity and Overweight
- Abdominal Obesity
- Overweight and/or Obesity
- Obesity & Overweight
- Genetic Obesity
- LEPR Deficiency Obesity
- PCSK1 Deficiency Obesity
- POMC Deficiency Obesity
- Childhood Obesity
- Healthy Volunteers Obesity
- Morbid Obesity
- Obese But Otherwise Healthy Participants
- Obesity Associated With Defects in Leptin-melanocortin Pathway
- Obesity and Cardiovascular Risk
- Obesity and Obesity-related Medical Conditions
- Obesity in Diabetes
- Obesity-related Complications
- Obesity/Overweight
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Obesity” (a text search, wider than this page)